Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: 48 Week Efficacy and Safety Results of a Phase II Randomized Placebo-Controlled Multicenter Trial

被引：0
|
作者：
Kappos, Ludwig
Li, David
Calabresi, Peter
O'Connor, Paul
Bar-Or, Amit
Barkhof, Frederik
Yin, Ming
Leppert, David
Glanzman, Robert
Tinbergen, Jeroen
Hauser, Stephen
机构：
来源：
NEUROLOGY | 2011年 / 76卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A545 / A545
页数：1
相关论文
共 50 条
  • [41] Low dose interleukin-2 in relapsing-remitting multiple sclerosis: A randomized double-blinded placebo-controlled trial
    Louapre, C.
    Rosenzwag, M.
    Golse, M.
    Galanaud, D.
    Papeix, C.
    Maillart, E.
    Ungureanu, A.
    Corvol, J. -C.
    Vicaut, E.
    Lubetzki, C.
    Klatzmann, D.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 550 - 551
  • [42] A placebo-controlled, randomized, double-blind, MRI trial of antiherpes therapy in patients with relapsing-remitting multiple sclerosis (RRMS)
    Jakobsen, J
    Bech, E
    Gadeberg, P
    Hansen, HJ
    Christensen, T
    Haahr, S
    Hollsberg, P
    Lycke, J
    Malmestrom, C
    Ekholm, S
    Bergstrom, T
    Svennerholm, B
    Andersen, O
    NEUROLOGY, 2001, 56 (08) : A74 - A74
  • [43] A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    Polman, CH
    O'Connor, PW
    Havrdova, E
    Hutchinson, M
    Kappos, L
    Miller, DH
    Phillips, JT
    Lublin, FD
    Giovannoni, G
    Wajgt, A
    Toal, M
    Lynn, F
    Panzara, MA
    Sandrock, AW
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09): : 899 - 910
  • [44] Efficacy of a Computer-Assisted Cognitive Rehabilitation Intervention in Relapsing-Remitting Multiple Sclerosis Patients: A Multicenter Randomized Controlled Trial
    Messinis, Lambros
    Nasios, Grigorios
    Kosmidis, Mary H.
    Zampakis, Petros
    Malefaki, Sonia
    Ntoskou, Katerina
    Nousia, Anastasia
    Bakirtzis, Christos
    Grigoriadis, Nikolaos
    Gourzis, Philippos
    Papathanasopoulos, Panagiotis
    BEHAVIOURAL NEUROLOGY, 2017, 2017
  • [45] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    DUQUETTE, P
    GIRARD, M
    DESPAULT, L
    DUBOIS, R
    KNOBLER, RL
    LUBLIN, FD
    KELLEY, L
    FRANCIS, GS
    LAPIERRE, Y
    ANTEL, J
    FREEDMAN, M
    HUM, S
    GREENSTEIN, JI
    MISHRA, B
    MULDOON, J
    WHITAKER, JN
    EVANS, BK
    LAYTON, B
    SIBLEY, WA
    LAGUNA, J
    KRIKAWA, J
    PATY, DW
    OGER, JJ
    KASTRUKOFF, LF
    MOORE, GRW
    HASHIMOTO, SA
    MORRISON, W
    NELSON, J
    GOODIN, DS
    MASSA, SM
    GUTTERIDGE, E
    ARNASON, BGW
    NORONHA, A
    REDER, AT
    MARTIA, R
    EBERS, GC
    RICE, GPA
    LESAUX, J
    JOHNSON, KP
    PANITCH, HS
    BEVER, CT
    CONWAY, K
    WALLENBERG, JC
    BEDELL, L
    VANDENNOORT, S
    WEINSHENKER, B
    WEISS, W
    REINGOLD, S
    PACHNER, A
    TAYLOR, W
    NEUROLOGY, 1993, 43 (04) : 655 - 661
  • [46] Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
    Sibley, WA
    NEUROLOGY, 2001, 57 (12) : S3 - S9
  • [47] Daclizumab phase I/II trial in relapsing-remitting multiple sclerosis: MRI and clinical results
    Rose, J.
    Burns, J.
    Bjorklund, J.
    Klein, J.
    Watt, H.
    Carlson, N.
    MULTIPLE SCLEROSIS, 2006, 12 : S105 - S105
  • [48] Efficacy and safety of opicinumab in participants with relapsing multiple sclerosis: a randomized, placebo-controlled, Phase 2 trial (AFFINITY Part 1)
    Calabresi, P. A.
    Giovannoni, G.
    Hartung, H. -P.
    Naismith, R. T.
    Fox, R.
    Sormani, M. -P.
    Arnold, D. L.
    Valis, M.
    Newsome, S. D.
    Bartholome, E.
    Belkin, M. I.
    Cheng, W.
    Ke, J.
    Riester, K.
    Javor, A.
    Lyons, J.
    Bradley, D. P.
    Fisher, E.
    Naylor, M. L.
    Belachew, S.
    Deykin, A.
    Franchimont, N.
    Zhu, B.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 90 - 91
  • [49] Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
    Sorensen, Per S.
    Lisby, Steen
    Grove, Richard
    Derosier, Frederick
    Shackelford, Steve
    Havrdova, Eva
    Drulovic, Jelena
    Filippi, Massimo
    NEUROLOGY, 2014, 82 (07) : 573 - 581
  • [50] Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial (vol 13, pg 545, 2014)
    Calabresi, P. A.
    Radue, E-W
    Goodin, D.
    LANCET NEUROLOGY, 2014, 13 (06): : 536 - 536
12345